PMID- 27417320
OWN - NLM
STAT- MEDLINE
DCOM- 20170322
LR  - 20181113
IS  - 1532-2807 (Electronic)
IS  - 1219-4956 (Linking)
VI  - 23
IP  - 1
DP  - 2017 Jan
TI  - Agreement of Different Methods for Tissue Based Detection of HER2 Signal in 
      Invasive Breast Cancer.
PG  - 79-84
LID - 10.1007/s12253-016-0091-4 [doi]
AB  - Breast cancer is the second leading cause of cancer mortality amongst American 
      women. The HER2 gene encodes a cell surface receptor that affects cell 
      proliferation and has been recognized as a diagnostic factor in treatment 
      selection for invasive breast cancer. Examine accuracy in HER2 detection between 
      manual count, computer assisted, and automated tiling algorithm. 42 randomly 
      selected invasive breast cancer specimens were enumerated by fluorescence in situ 
      hybridization (FISH)for HER2 and CEP17 markers using the Vysis HER2 assay 
      (AbbotLaboratory, North Chicago, IL). Specimens were tested using three methods: 
      Manual, computer assisted nuclei selection (Tissue FISH MetaSystems, Newton, MA), 
      and automated enumeration (MetaSystems, Newton, MA). The greatest bias and widest 
      agreement limits for HER2 and CEP17 were seen in Automatic versus Manual, the 
      gold standard. HER2 values greater than 6 possessed the greatest bias and widest 
      agreement limits. CEP17 comparison showed similar bias and agreement limits for 
      each comparison. Kappa values indicated good agreement for all methods although 
      Tissue FISH and Manual possessed better agreement. Higher agreement at lower HER2 
      & CEP17 count maybe due to fewer chromosomal aberrations, in which selection of 
      field of views has less variation between methods. Alternatively, increased 
      background signals seen in polyploidy may be responsible for the variations in 
      signal count. Manual and Tissue FISH demonstrated good agreement amongst by both 
      Altman Bland and Cohen's Kappa. While the automatic method has good agreement at 
      lower HER2, the sharp increase in variability at higher HER2 counts illustrates a 
      limitation of the automatic method.
FAU - Thakral, Gaurav
AU  - Thakral G
AD  - University of Hawaii West, Honolulu, HI, USA. gthakral@hawaii.edu.
FAU - Wey, Andrew
AU  - Wey A
AD  - University of Hawaii West, Honolulu, HI, USA.
FAU - Rahman, Mobeen
AU  - Rahman M
AD  - University of Hawaii West, Honolulu, HI, USA.
FAU - Fang, Rui
AU  - Fang R
AD  - University of Hawaii West, Honolulu, HI, USA.
FAU - Lum, Christopher
AU  - Lum C
AD  - University of Hawaii West, Honolulu, HI, USA.
LA  - eng
PT  - Journal Article
DEP - 20160714
PL  - Switzerland
TA  - Pathol Oncol Res
JT  - Pathology oncology research : POR
JID - 9706087
RN  - EC 2.7.10.1 (ERBB2 protein, human)
RN  - EC 2.7.10.1 (Receptor, ErbB-2)
SB  - IM
MH  - Algorithms
MH  - Breast Neoplasms/*diagnosis/*genetics/pathology
MH  - Cell Proliferation/genetics
MH  - Chromosome Aberrations
MH  - Female
MH  - Humans
MH  - Middle Aged
MH  - Neoplasm Invasiveness/*diagnosis/*genetics/pathology
MH  - Receptor, ErbB-2/*genetics
MH  - Signal Transduction/*genetics
OTO - NOTNLM
OT  - Altman bland
OT  - Breast neoplasms/diagnosis
OT  - Breast neoplasms/treatment
OT  - Fish
OT  - HER2 Recptor
EDAT- 2016/07/16 06:00
MHDA- 2017/03/23 06:00
CRDT- 2016/07/16 06:00
PHST- 2015/06/28 00:00 [received]
PHST- 2016/07/06 00:00 [accepted]
PHST- 2016/07/16 06:00 [pubmed]
PHST- 2017/03/23 06:00 [medline]
PHST- 2016/07/16 06:00 [entrez]
AID - 10.1007/s12253-016-0091-4 [pii]
AID - 10.1007/s12253-016-0091-4 [doi]
PST - ppublish
SO  - Pathol Oncol Res. 2017 Jan;23(1):79-84. doi: 10.1007/s12253-016-0091-4. Epub 2016 
      Jul 14.